Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.
Identifieur interne : 000A75 ( Main/Exploration ); précédent : 000A74; suivant : 000A76Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.
Auteurs : Philippe Caron [France]Source :
- Annales d'endocrinologie [ 2213-3941 ] ; 2020.
Descripteurs français
- KwdFr :
- Apoptose (MeSH), Betacoronavirus (MeSH), Glande thyroide (anatomopathologie), Glande thyroide (composition chimique), Glande thyroide (physiopathologie), Hormones thyroïdiennes (sang), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Hypophyse (physiopathologie), Hypothyroïdie (physiopathologie), Hypothyroïdie (sang), Hypothyroïdie (étiologie), Infections à coronavirus (complications), Infections à coronavirus (physiopathologie), Infections à coronavirus (traitement médicamenteux), Interleukine-6 (physiologie), Maladies de la thyroïde (physiopathologie), Maladies de la thyroïde (sang), Maladies de la thyroïde (étiologie), Ophtalmopathie basedowienne (complications), Pandémies (MeSH), Peptidyl-Dipeptidase A (analyse), Pneumopathie virale (complications), Pneumopathie virale (physiopathologie), Pneumopathie virale (traitement médicamenteux), Prédisposition aux maladies (MeSH), Récepteurs viraux (analyse), Thyréostimuline (sang), Thyréotoxicose (physiopathologie), Thyréotoxicose (sang), Thyréotoxicose (étiologie).
- MESH :
- analyse : Peptidyl-Dipeptidase A, Récepteurs viraux.
- anatomopathologie : Glande thyroide.
- composition chimique : Glande thyroide, Infections à coronavirus, Ophtalmopathie basedowienne, Pneumopathie virale.
- effets indésirables : Hydroxychloroquine.
- physiologie : Interleukine-6.
- physiopathologie : Glande thyroide, Hypophyse, Hypothyroïdie, Infections à coronavirus, Maladies de la thyroïde, Pneumopathie virale, Thyréotoxicose.
- sang : Hormones thyroïdiennes, Hypothyroïdie, Maladies de la thyroïde, Thyréostimuline, Thyréotoxicose.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Hydroxychloroquine.
- étiologie : Hypothyroïdie, Maladies de la thyroïde, Thyréotoxicose.
- Apoptose, Betacoronavirus, Humains, Pandémies, Prédisposition aux maladies.
English descriptors
- KwdEn :
- Angiotensin-Converting Enzyme 2 (MeSH), Apoptosis (MeSH), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (physiopathology), Cytokine Release Syndrome (etiology), Cytokine Release Syndrome (physiopathology), Disease Susceptibility (MeSH), Graves Ophthalmopathy (complications), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Hypothyroidism (blood), Hypothyroidism (etiology), Hypothyroidism (physiopathology), Interleukin-6 (physiology), Pandemics (MeSH), Peptidyl-Dipeptidase A (analysis), Pituitary Gland (physiopathology), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (physiopathology), Receptors, Virus (analysis), SARS-CoV-2 (MeSH), Thyroid Diseases (blood), Thyroid Diseases (etiology), Thyroid Diseases (physiopathology), Thyroid Gland (chemistry), Thyroid Gland (pathology), Thyroid Gland (physiopathology), Thyroid Hormones (blood), Thyrotoxicosis (blood), Thyrotoxicosis (etiology), Thyrotoxicosis (physiopathology), Thyrotropin (blood).
- MESH :
- chemical , adverse effects : Hydroxychloroquine.
- chemical , analysis : Peptidyl-Dipeptidase A, Receptors, Virus.
- chemical , blood : Thyroid Hormones, Thyrotropin.
- chemical , physiology : Interleukin-6.
- chemical , therapeutic use : Hydroxychloroquine.
- chemical : Angiotensin-Converting Enzyme 2.
- blood : Hypothyroidism, Thyroid Diseases, Thyrotoxicosis.
- chemistry : Thyroid Gland.
- complications : Coronavirus Infections, Graves Ophthalmopathy, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- etiology : Cytokine Release Syndrome, Hypothyroidism, Thyroid Diseases, Thyrotoxicosis.
- pathology : Thyroid Gland.
- physiopathology : Coronavirus Infections, Cytokine Release Syndrome, Hypothyroidism, Pituitary Gland, Pneumonia, Viral, Thyroid Diseases, Thyroid Gland, Thyrotoxicosis.
- Apoptosis, Betacoronavirus, COVID-19, Disease Susceptibility, Humans, Pandemics, SARS-CoV-2.
Abstract
The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.
DOI: 10.1016/j.ando.2020.09.001
PubMed: 32950466
PubMed Central: PMC7498405
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.</title>
<author><name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name>
<affiliation wicri:level="3"><nlm:affiliation>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32950466</idno>
<idno type="pmid">32950466</idno>
<idno type="doi">10.1016/j.ando.2020.09.001</idno>
<idno type="pmc">PMC7498405</idno>
<idno type="wicri:Area/Main/Corpus">000B91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B91</idno>
<idno type="wicri:Area/Main/Curation">000B91</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B91</idno>
<idno type="wicri:Area/Main/Exploration">000B91</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.</title>
<author><name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name>
<affiliation wicri:level="3"><nlm:affiliation>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Annales d'endocrinologie</title>
<idno type="eISSN">2213-3941</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Apoptosis (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Cytokine Release Syndrome (etiology)</term>
<term>Cytokine Release Syndrome (physiopathology)</term>
<term>Disease Susceptibility (MeSH)</term>
<term>Graves Ophthalmopathy (complications)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Hypothyroidism (blood)</term>
<term>Hypothyroidism (etiology)</term>
<term>Hypothyroidism (physiopathology)</term>
<term>Interleukin-6 (physiology)</term>
<term>Pandemics (MeSH)</term>
<term>Peptidyl-Dipeptidase A (analysis)</term>
<term>Pituitary Gland (physiopathology)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (physiopathology)</term>
<term>Receptors, Virus (analysis)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Thyroid Diseases (blood)</term>
<term>Thyroid Diseases (etiology)</term>
<term>Thyroid Diseases (physiopathology)</term>
<term>Thyroid Gland (chemistry)</term>
<term>Thyroid Gland (pathology)</term>
<term>Thyroid Gland (physiopathology)</term>
<term>Thyroid Hormones (blood)</term>
<term>Thyrotoxicosis (blood)</term>
<term>Thyrotoxicosis (etiology)</term>
<term>Thyrotoxicosis (physiopathology)</term>
<term>Thyrotropin (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Apoptose (MeSH)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Glande thyroide (anatomopathologie)</term>
<term>Glande thyroide (composition chimique)</term>
<term>Glande thyroide (physiopathologie)</term>
<term>Hormones thyroïdiennes (sang)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Hypophyse (physiopathologie)</term>
<term>Hypothyroïdie (physiopathologie)</term>
<term>Hypothyroïdie (sang)</term>
<term>Hypothyroïdie (étiologie)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (physiopathologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Interleukine-6 (physiologie)</term>
<term>Maladies de la thyroïde (physiopathologie)</term>
<term>Maladies de la thyroïde (sang)</term>
<term>Maladies de la thyroïde (étiologie)</term>
<term>Ophtalmopathie basedowienne (complications)</term>
<term>Pandémies (MeSH)</term>
<term>Peptidyl-Dipeptidase A (analyse)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (physiopathologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Prédisposition aux maladies (MeSH)</term>
<term>Récepteurs viraux (analyse)</term>
<term>Thyréostimuline (sang)</term>
<term>Thyréotoxicose (physiopathologie)</term>
<term>Thyréotoxicose (sang)</term>
<term>Thyréotoxicose (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
<term>Receptors, Virus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Thyroid Hormones</term>
<term>Thyrotropin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiotensin-Converting Enzyme 2</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term>
<term>Récepteurs viraux</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Glande thyroide</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hypothyroidism</term>
<term>Thyroid Diseases</term>
<term>Thyrotoxicosis</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Thyroid Gland</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Graves Ophthalmopathy</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Glande thyroide</term>
<term>Infections à coronavirus</term>
<term>Ophtalmopathie basedowienne</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cytokine Release Syndrome</term>
<term>Hypothyroidism</term>
<term>Thyroid Diseases</term>
<term>Thyrotoxicosis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Thyroid Gland</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Interleukine-6</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Glande thyroide</term>
<term>Hypophyse</term>
<term>Hypothyroïdie</term>
<term>Infections à coronavirus</term>
<term>Maladies de la thyroïde</term>
<term>Pneumopathie virale</term>
<term>Thyréotoxicose</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Cytokine Release Syndrome</term>
<term>Hypothyroidism</term>
<term>Pituitary Gland</term>
<term>Pneumonia, Viral</term>
<term>Thyroid Diseases</term>
<term>Thyroid Gland</term>
<term>Thyrotoxicosis</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hormones thyroïdiennes</term>
<term>Hypothyroïdie</term>
<term>Maladies de la thyroïde</term>
<term>Thyréostimuline</term>
<term>Thyréotoxicose</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hypothyroïdie</term>
<term>Maladies de la thyroïde</term>
<term>Thyréotoxicose</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Apoptosis</term>
<term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Disease Susceptibility</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Apoptose</term>
<term>Betacoronavirus</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Prédisposition aux maladies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32950466</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3941</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>81</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Annales d'endocrinologie</Title>
<ISOAbbreviation>Ann Endocrinol (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.</ArticleTitle>
<Pagination><MedlinePgn>507-510</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0003-4266(20)31214-2</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ando.2020.09.001</ELocationID>
<Abstract><AbstractText>The World Health Organization (WHO) declared the COVID-19 epidemic to be a global pandemic in March 2020. COVID-19 is an infection caused by SARS-CoV-2, a coronavirus that utilizes the angiotensin-2 converting enzyme to penetrate thyroid and pituitary cells, and may result in a "cytokine storm". Based on the pathophysiological involvement of the pituitary-thyroid axis, the current review discusses the diagnosis of abnormal thyroid function test, and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caron</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Ann Endocrinol (Paris)</MedlineTA>
<NlmUniqueID>0116744</NlmUniqueID>
<ISSNLinking>0003-4266</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9002-71-5</RegistryNumber>
<NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010902" MajorTopicYN="N">Pituitary Gland</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013971" MajorTopicYN="N">Thyrotoxicosis</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Free T3</Keyword>
<Keyword MajorTopicYN="N">Free T4</Keyword>
<Keyword MajorTopicYN="N">Hypothyroidism</Keyword>
<Keyword MajorTopicYN="N">Hypothyroïdie</Keyword>
<Keyword MajorTopicYN="N">Orbitopathie</Keyword>
<Keyword MajorTopicYN="N">Orbitopathy</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">T3l</Keyword>
<Keyword MajorTopicYN="N">T4l</Keyword>
<Keyword MajorTopicYN="N">TSH</Keyword>
<Keyword MajorTopicYN="N">Thyrotoxicose</Keyword>
<Keyword MajorTopicYN="N">Thyrotoxicosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>20</Day>
<Hour>20</Hour>
<Minute>26</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32950466</ArticleId>
<ArticleId IdType="pii">S0003-4266(20)31214-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.ando.2020.09.001</ArticleId>
<ArticleId IdType="pmc">PMC7498405</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Endocrinol Invest. 2020 Aug;43(8):1171-1172</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32488726</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2020 Nov 5;886:173451</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32768505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Endocrinol Invest. 2020 Aug;43(8):1149-1151</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32441005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Endocrinol (Oxf). 2005 Aug;63(2):197-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16060914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32738929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2009 Jan 12;6:5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19138419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocrinology. 2020 Sep 1;161(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32652001</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Endocrinol Invest. 2020 Aug;43(8):1173-1174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32504458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2020 Jul;75(7):1730-1741</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32172546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thyroid. 2020 Jul 10;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32600165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hormones (Athens). 2020 Jul 16;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32676935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Diabetes Endocrinol. 2015 Oct;3(10):816-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26071885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Syndr. 2020 Sep - Oct;14(5):767-771</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32521463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Cell Biol. 2010 Aug;88(4):723-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20651845</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Postgrad Med J. 2020 Jul;96(1137):412-416</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32527756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2020 Oct 1;105(10):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32780854</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Endocrinol. 2020 Jul;183(1):G33-G39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32438340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Endocrinol Invest. 2020 Aug;43(8):1169-1170</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32488724</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thyroid. 1998 Jan;8(1):37-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9492151</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Mar 26;368:m1091</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217556</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Endocrine. 2020 Jun;68(3):471-474</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32507963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Immunol Infect. 2020 Jun;53(3):368-370</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Horm Metab Res. 2020 Jul;52(7):471-484</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32512611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2020 Aug 1;105(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32525973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Endocrinol Invest. 2020 Jul;43(7):1027-1031</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32361826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2020 Jun 1;105(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32249902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Dis Poverty. 2020 Apr 28;9(1):45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32345362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Pathol. 2007 Jan;38(1):95-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16996569</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Endocrinol. 2020 Oct;183(4):381-387</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32698147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 21;382(21):2012-2022</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227758</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 2020 Jul 1;105(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32436948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 1997 May 31;314(7094):1593</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9186170</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32950466 |texte= Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32950466" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |